10 November 2017

Sir John Banham retires from Board of Directors of Arix Bioscience plc

 

LONDON, 10 November 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Sir John Banham is retiring from his position as a Non-Executive Director of Arix Bioscience.

 

Sir John, who is 76, has been Chairman of the Audit and Risk Committee, and has helped to oversee the Company’s growth both as a private company and since its successful IPO on the London Stock Exchange in February 2017. As previously announced, Giles Kerr joined the Board of Arix on 17 October 2017 and will succeed Sir John as Chairman of the Audit and Risk Committee.

“It has been a pleasure and a privilege to work with Sir John. On behalf of the Board, I would like to thank him for his many contributions to the successful creation and early development of Arix Bioscience.”

Jonathan Peacock

Chairman of Arix Bioscience

For more information, please contact:

 

Arix Bioscience plc

Matthew Cole, Communications Director

+44 (0) 20 7290 1065

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

 

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com


Back to previous page